Scholarlink

Background <p>There is variability in overall survival among 2021 World Health Organization isocitrate dehydrogenase wild type glioblastoma (IDH-wt GBM) patients. The aim of the study was to develop a combined model for stratifying survival risk in IDH-wt GBM and explore the biological foundation.</p> Methods <p>A total of 369 IDH-wt GBM patients were retrospectively collected: 273 patients from three local hospitals (training set: <i>n</i> = 192, testing set: <i>n</i> = 81) and 96 patients from the TCIA database (validation set). Radiomics features from tumor and peritumoral edema in preoperative CE-T1WI and T2FLAIR were extracted. Univariate and least absolute shrinkage and selection operator Cox regression analyses selected significant radiomics features to construct radiomics model, while univariable and multivariable analyses identified clinical risk factors for the clinical model. High-risk and low-risk patients from radiomics and clinical model underwent subgroup analysis. The combined model was constructed using the Random Survival Forest model. Additionally, differentially expressed genes between combined high-risk and low-risk groups were identified, with enrichment analyses exploring their biological mechanisms.</p> Results <p>The radiomics model categorizes patients into high-risk and low-risk groups with superior performance (C-index: 0.762/0.715/0.690 for training/testing/validation sets) compared to the clinical model (C-index: 0.700/0.656/0.643). The combined model demonstrates the highest value in survival risk stratification (C-index: training/testing/validation sets: 0.788/0.725/0.709). The activation of Gamma-aminobutyric acid (GABA) receptor-related pathways is closely associated with malignant progression and prognosis of IDH-wt GBM.</p> Conclusions <p>The radiomics model might be a new prognostic biomarker for IDH-wt GBM. The combined model shows an approximately 12.57% improvement of stratification ability over the clinical model. Additionally, the significant activation of GABA receptor-related pathways may be a biological feature of combined high-risk IDH-wt GBM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月3日

查看全文
  • Yangyang Li,
  • Wenji Xu,
  • Chunjuan Zhao,
  • Jie Zhang,
  • Zhiyi Zhang,
  • Pengxin Shen,
  • Xiaochun Wang,
  • Guoqiang Yang,
  • Jiangfeng Du,
  • Hui Zhang,
  • Yan Tan

摘要

Background

There is variability in overall survival among 2021 World Health Organization isocitrate dehydrogenase wild type glioblastoma (IDH-wt GBM) patients. The aim of the study was to develop a combined model for stratifying survival risk in IDH-wt GBM and explore the biological foundation.

Methods

A total of 369 IDH-wt GBM patients were retrospectively collected: 273 patients from three local hospitals (training set: n = 192, testing set: n = 81) and 96 patients from the TCIA database (validation set). Radiomics features from tumor and peritumoral edema in preoperative CE-T1WI and T2FLAIR were extracted. Univariate and least absolute shrinkage and selection operator Cox regression analyses selected significant radiomics features to construct radiomics model, while univariable and multivariable analyses identified clinical risk factors for the clinical model. High-risk and low-risk patients from radiomics and clinical model underwent subgroup analysis. The combined model was constructed using the Random Survival Forest model. Additionally, differentially expressed genes between combined high-risk and low-risk groups were identified, with enrichment analyses exploring their biological mechanisms.

Results

The radiomics model categorizes patients into high-risk and low-risk groups with superior performance (C-index: 0.762/0.715/0.690 for training/testing/validation sets) compared to the clinical model (C-index: 0.700/0.656/0.643). The combined model demonstrates the highest value in survival risk stratification (C-index: training/testing/validation sets: 0.788/0.725/0.709). The activation of Gamma-aminobutyric acid (GABA) receptor-related pathways is closely associated with malignant progression and prognosis of IDH-wt GBM.

Conclusions

The radiomics model might be a new prognostic biomarker for IDH-wt GBM. The combined model shows an approximately 12.57% improvement of stratification ability over the clinical model. Additionally, the significant activation of GABA receptor-related pathways may be a biological feature of combined high-risk IDH-wt GBM.